Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Editas Medicine (Nasdaq: EDIT) announced that the FDA has granted Orphan Drug Designation to its investigational gene editing medicine EDIT-301 for treating sickle cell disease. This designation recognizes the urgent need for new therapies for a condition affecting around 100,000 individuals in the U.S.
The company aims to dose 20 patients in the ongoing RUBY trial by year-end, with clinical data updates expected mid-2023 and by year-end. EDIT-301 is also under investigation for treating transfusion-dependent beta thalassemia. The Orphan Drug Designation offers various incentives, including tax credits and potential marketing exclusivity upon FDA approval.
President and CEO Gilmore O’Neill emphasized the potential of EDIT-301 to provide significant clinical benefits to patients.
Editas Medicine (Nasdaq: EDIT) announced the appointment of Emma Reeve as Chair of the Board, effective at the next annual stockholder meeting on June 1, 2023. Reeve replaces James C. Mullen, who is stepping down. Additionally, Elliott Levy, M.D., joins the Board as an Independent Director. Reeve, who has been on the Board since September 2021, brings over 25 years of biopharmaceutical experience. Her leadership in overseeing the recent strategic changes at Editas positions her well for this role. Dr. Levy, an accomplished biopharmaceutical executive with extensive R&D experience, is expected to enhance the company’s drug development efforts. Dr. O’Neill, the CEO, expressed confidence in the new leadership while thanking Mullen for his contributions over the last five years.